Literature DB >> 30081723

CRMP4a suppresses cell motility by sequestering RhoA activity in prostate cancer cells.

Changlin Li1, Haixia Xu2, Lin Xiao3, Haizhou Zhu3, Guoan Zhang4, Wei Wei5, Kaizhi Li6, Xiande Cao3, Daqing Shen3, Jeffrey Holzbeierlein2, Benyi Li2.   

Abstract

Objectives: Distant metastasis is a critical factor for cancer-associated death. Our previous studies identified collapsin response mediator protein 4a (CRMP4a) as a metastasis suppressor in prostate cancers. Enhancing CRMP4 expression by promoter-targeted small activating RNAs reduced cell migration in vitro and abolished distal metastasis in mouse xenograft models. In this study, we investigated the mechanism for CRMP4a-mediated suppression of cell migration.
Methods: PC-3 cells were stably infected with lentiviruses expressing CRMP4a cDNA or a shRNA sequence. Cytoskeletal organization was analyzed by measuring cellular focal adhesion area and number, percentage of cell area and lamellipodia numbers after phalloidin staining or anti-vinculin immunocytofluorescent staining. Cell migration was evaluated with TranswellTM chambers coated with MatriGel. RhoA activation was determined with a Rhotekin RBD agarose bead-based assay kit. Lentiviruses harboring RhoA-Q63L or RhoA-T19N mutant constructs were used to overexpress mutant RhoA proteins.
Results: CRMP4a overexpression largely reduced while CRMP4a knockdown remarkably increased cytoskeletal organization in PC-3 cells. CRMP4a immunoprecipitation pulled down RhoA but not cdc42 or Rac1 proteins. Manipulating CRMP4a expression levels reversely altered active RhoA levels. Overexpression of RhoA active (Q63L) but not inactive (T19N) mutants reversed CRMP4a-mediated reduction of cancer cell migration while RhoA inhibitor Rhosin diminished CRMP4a shRNA-induced increase of cancer cell migration. CRMP4a overexpression also largely reduced cell spreading that was abolished by overexpressing RhoA active mutant.
Conclusion: Our data demonstrated that CRMP4a interacts with RhoA and sequesters its activity, resulting in suppression of cytoskeletal organization, cell migration and spreading.

Entities:  

Keywords:  CRMP4a; RhoA; cell motility; prostate cancer

Year:  2018        PMID: 30081723      PMCID: PMC6301799          DOI: 10.1080/15384047.2018.1491507

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  29 in total

1.  p80 ROKalpha binding protein is a novel splice variant of CRMP-1 which associates with CRMP-2 and modulates RhoA-induced neuronal morphology.

Authors:  Thomas Leung; Yvonne Ng; Albert Cheong; Chong Han Ng; Ivan Tan; Christine Hall; Louis Lim
Journal:  FEBS Lett       Date:  2002-12-18       Impact factor: 4.124

2.  Collapsin response mediator protein-4 regulates F-actin bundling.

Authors:  Volker Rosslenbroich; Lingsong Dai; Stephan L Baader; Angelika A Noegel; Volkmar Gieselmann; Joachim Kappler
Journal:  Exp Cell Res       Date:  2005-09-21       Impact factor: 3.905

3.  Identification of CRMP4 as a convergent regulator of axon outgrowth inhibition.

Authors:  Yazan Z Alabed; Madeline Pool; Stephan Ong Tone; Alyson E Fournier
Journal:  J Neurosci       Date:  2007-02-14       Impact factor: 6.167

4.  Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer.

Authors:  X Gao; J Pang; L-Y Li; W-P Liu; J-M Di; Q-P Sun; Y-Q Fang; X-P Liu; X-Y Pu; D He; M-T Li; Z-L Su; B-Y Li
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

5.  Upregulation of CRMP4, a new prostate cancer metastasis suppressor gene, inhibits tumor growth in a nude mouse intratibial injection model.

Authors:  Wei Zhou; Peigen Xie; Mao Pang; Bu Yang; Youqiang Fang; Tao Shu; Chang Liu; Xuan Wang; Liangming Zhang; Shangfu Li; Limin Rong
Journal:  Int J Oncol       Date:  2014-10-10       Impact factor: 5.650

6.  Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases.

Authors:  Xin Gao; Liao-Yuan Li; Jörg Rassler; Jun Pang; Ming-Kun Chen; Wei-Peng Liu; Zheng Chen; Shan-Cheng Ren; Fang-Jian Zhou; Ke-Ji Xie; Xing Zhou; Hui-Jun Qian; Xian-Zhong Bai; Jiu-Min Liu; Jiang-Gen Yang; Dan He; Chun-Kui Shao; Zu-Lan Su; Jing Wang; Jian-Guang Qiu; Li Ling
Journal:  J Natl Cancer Inst       Date:  2017-01-25       Impact factor: 13.506

Review 7.  Rho GTPases: Regulation and roles in cancer cell biology.

Authors:  Raquel B Haga; Anne J Ridley
Journal:  Small GTPases       Date:  2016-09-14

Review 8.  Targeting metastasis.

Authors:  Patricia S Steeg
Journal:  Nat Rev Cancer       Date:  2016-04       Impact factor: 60.716

9.  Collapsin response mediator protein 4 regulates growth cone dynamics through the actin and microtubule cytoskeleton.

Authors:  Mohamad R Khazaei; Marie-Pier Girouard; Ricardo Alchini; Stephan Ong Tone; Tadayuki Shimada; Susanne Bechstedt; Mitra Cowan; Dominique Guillet; Paul W Wiseman; Gary Brouhard; Jean Francois Cloutier; Alyson E Fournier
Journal:  J Biol Chem       Date:  2014-09-15       Impact factor: 5.157

Review 10.  Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion.

Authors:  Shuh Narumiya; Masahiro Tanji; Toshimasa Ishizaki
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

View more
  4 in total

1.  Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.

Authors:  Changlin Li; Hui Sun; Wei Wei; Qiuzi Liu; Yinglei Wang; Ying Zhang; Fuming Lian; Fangchao Liu; Chenchen Li; Kaicheng Ying; Hang Huo; Zhi Qi; Benyi Li
Journal:  Cell Oncol (Dordr)       Date:  2020-07-24       Impact factor: 6.730

2.  Alternol triggers immunogenic cell death via reactive oxygen species generation.

Authors:  Changlin Li; Ying Zhang; Siyuan Yan; Guoan Zhang; Wei Wei; Zhi Qi; Benyi Li
Journal:  Oncoimmunology       Date:  2021-07-21       Impact factor: 8.110

Review 3.  Ten years of research on the role of BVES/ POPDC1 in human disease: a review.

Authors:  Ping Han; Yu Lei; Dongxiao Li; Jingmei Liu; Wei Yan; Dean Tian
Journal:  Onco Targets Ther       Date:  2019-02-18       Impact factor: 4.147

4.  Low Incidence of High-Grade Pancreatic Intraepithelial Neoplasia Lesions in a Crmp4 Gene-Deficient Mouse Model of Pancreatic Cancer.

Authors:  Keiichi Yazawa; Fumio Nakamura; Daiki Masukawa; Sho Sato; Yukihiko Hiroshima; Yasuhiro Yabushita; Ryutaro Mori; Ryusei Matsuyama; Ikuma Kato; Hideki Taniguchi; Yoshio Goshima; Itaru Endo
Journal:  Transl Oncol       Date:  2020-02-24       Impact factor: 4.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.